Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population

Background and Aim: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. Methods: A comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both in vivo and in vitro studies were considered. Results: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17–50%), IBS-D (37–62%) and IBS-C (4–25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). Conclusions: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

Download Full-text

Blastocystis specific serum immunoglobulin in patients with irritable bowel syndrome (IBS) versus healthy controls

Parasites & Vectors ◽

10.1186/s13071-015-1069-x ◽

2015 ◽

Vol 8 (1) ◽

Cited By ~ 9

Author(s):

Robyn Nagel ◽

Rebecca J. Traub ◽

Marcella M S Kwan ◽

Helle Bielefeldt-Ohmann

Keyword(s):

Irritable Bowel Syndrome ◽

Serum Immunoglobulin ◽

Healthy Controls ◽

Specific Serum ◽

Irritable Bowel

Download Full-text

Temporal Summation in Patients With Irritable Bowel Syndrome (IBS) Compared to Healthy Controls (HC)

Gastroenterology ◽

10.1016/s0016-5085(11)62234-8 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-539

Author(s):

Steve Heymen ◽

Olafur S. Palsson ◽

William Maixner ◽

Lisa M. Gangarosa ◽

Susan Girdler ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Temporal Summation ◽

Healthy Controls ◽

Irritable Bowel

Download Full-text

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.15141 ◽

2019 ◽

Vol 49 (6) ◽

pp. 723-732 ◽

Cited By ~ 9

Author(s):

Ammar Hassanzadeh Keshteli ◽

Karen L. Madsen ◽

Rupasri Mandal ◽

Guy E. Boeckxstaens ◽

Premysl Bercik ◽

...

Keyword(s):

Ulcerative Colitis ◽

Irritable Bowel Syndrome ◽

Healthy Controls ◽

Irritable Bowel ◽

Potential Biomarkers

Download Full-text

IMAGINE Network’s Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome

BMJ Open ◽

10.1136/bmjopen-2020-041733 ◽

2020 ◽

Vol 10 (10) ◽

pp. e041733

Author(s):

Paul Moayyedi ◽

Glenda MacQueen ◽

Charles N Bernstein ◽

Stephen Vanner ◽

Premysl Bercik ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Irritable Bowel Syndrome ◽

Cohort Study ◽

Bowel Disease ◽

Gut Microbiome ◽

Psychological Status ◽

Healthy Controls ◽

Gi Symptoms ◽

Inflammatory Bowel ◽

Irritable Bowel

IntroductionGut microbiome and diet may be important in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and comorbid psychiatric conditions, but the mechanisms are unclear. We will create a large cohort of patients with IBS, IBD and healthy controls, and follow them over time, collecting dietary and mental health information and biological samples, to assess their gastrointestinal (GI) and psychological symptoms in association with their diet, gut microbiome and metabolome.Methods and analysisThis 5-year observational prospective cohort study is recruiting 8000 participants from 15 Canadian centres. Persons with IBS who are 13 years of age and older or IBD ≥5 years will be recruited. Healthy controls will be recruited from the general public and from friends or relatives of those with IBD or IBS who do not have GI symptoms. Participants answer surveys and provide blood, urine and stool samples annually. Surveys assess disease activity, quality of life, physical pain, lifestyle factors, psychological status and diet. The main outcomes evaluated will be the association between the diet, inflammatory, genetic, microbiome and metabolomic profiles in those with IBD and IBS compared with healthy controls using multivariate logistic regression. We will also compare these profiles in those with active versus quiescent disease and those with and without psychological comorbidity.Ethics and disseminationApproval has been obtained from the institutional review boards of all centres taking part in the study. We will develop evidence-based knowledge translation initiatives for patients, clinicians and policymakers to disseminate results to relevant stakeholders.Trial registration number:NCT03131414

Download Full-text

Healthy Controls Are Not Appropriately Identified for Comparison to Irritable Bowel Syndrome in Case Control Studies

Gastroenterology ◽

10.1016/s0016-5085(11)63311-8 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-799 ◽

Cited By ~ 1

Author(s):

Shireen Ghorbani ◽

Amir Nejad ◽

David Law ◽

Kathleen Chua ◽

Meridythe M. Amichai ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Case Control ◽

Healthy Controls ◽

Case Control Studies ◽

Irritable Bowel

Download Full-text

Mass spectrometry-based metabolomics for irritable bowel syndrome biomarkers

Therapeutic Advances in Gastroenterology ◽

10.1177/1756284819886425 ◽

2019 ◽

Vol 12 ◽

pp. 175628481988642 ◽

Cited By ~ 2

Author(s):

Qihong Yu ◽

Xinru Liu ◽

Haojie Huang ◽

Xingfeng Zheng ◽

Xue Pan ◽

...

Keyword(s):

Mass Spectrometry ◽

Irritable Bowel Syndrome ◽

Gastrointestinal Disorder ◽

Ultra Performance Liquid Chromatography ◽

Healthy Controls ◽

Multivariate Statistical ◽

Clinical Trial Registration ◽

Flight Mass Spectrometry ◽

Hormone Biosynthesis ◽

Irritable Bowel

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder without obvious structural abnormalities or consistent associated biomarkers, making its diagnosis difficult. In the present study, we used a urine-based metabolomics approach to identify IBS biomarkers. Methods: We used an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS) on urine samples from patients suffering from IBS and healthy controls. Data were coupled for multivariate statistical analysis methods. Results: We selected 30 differential metabolites associated with IBS and found steroid hormone biosynthesis and histidine metabolism alterations in patients with IBS that may be involved in the pathogenesis of the disease. In addition, we identified a panel of five metabolite markers composed of cortisone, citric acid, tiglylcarnitine, N6,-N6,-N6-trimethyl-L-lysine and L-histidine that could be used to discriminate between patients and healthy controls and may be appropriate as IBS diagnosis biomarkers. Conclusion: Our findings indicate that metabolomics combined with pattern recognition can be useful to identify disease diagnostic IBS markers. Clinical trial registration: ChiCTR1800020072

Download Full-text

Irritable bowel syndrome in Egyptian patients: plausible risk factors and association with intestinal protozoa

Tropical Doctor ◽

10.1177/0049475519837112 ◽

2019 ◽

Vol 49 (3) ◽

pp. 184-188 ◽

Cited By ~ 1

Author(s):

Aziza I Salem ◽

Hend A El-Taweel ◽

Marwa A Madkour ◽

Naglaa F Abd El-Latif ◽

Ebtesam S Abd-Elrazeq

Keyword(s):

Risk Factors ◽

Irritable Bowel Syndrome ◽

Parasitic Infection ◽

Gastrointestinal Symptoms ◽

Positive Association ◽

Healthy Controls ◽

Blastocystis Hominis ◽

Intestinal Protozoa ◽

Group I ◽

Irritable Bowel

The pathogenesis of irritable bowel syndrome (IBS) is not yet clear. Our study suggested parasitic infection and other plausible risk factors among Egyptian IBS patients. We studied 40 IBS patients diagnosed according to Rome III criteria (Group I), 40 with other gastrointestinal symptoms (Group II) and 40 healthy controls (Group III). Stool samples were examined using direct wet smear, sedimentation technique, trichrome stain and immune-chromatographic tests for Cryptosporidium parvum. IBS patients displayed a significantly greater percentage of Blastocystis hominis infection (45%) than non-IBS patients (20%) and healthy controls (10%). Dientamoeba fragilis was identified in two IBS patients. Detection of B. hominis was independent of demographic characters, IBS subtype, Helicobacter pylori infection or medications, but with a positive association with a history of antibiotic intake with IBS.

Download Full-text